- AbbVie has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) and signed a Letter of Intent for Elahere (mirvetuximab soravtansine), advancing the treatment toward potential public reimbursement.
- Elahere is an antibody-drug conjugate for FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer in patients who have received 1–3 prior systemic treatment regimens.
- Elahere is the first novel targeted monotherapy to demonstrate statistically significant and clinically meaningful overall survival improvements versus single-agent chemotherapy in FRα-positive, platinum-resistant ovarian cancer.
- The agreement brings eligible patients closer to access through provincial and territorial public drug plans. Further collaboration is needed to support timely reimbursement and equitable access across Canada.
Takeaways:
Elahere’s pCPA agreement advances AbbVie’s efforts to expand access to targeted treatment for FRα-positive, platinum-resistant ovarian cancer in Canada. Its demonstrated overall survival benefit versus chemotherapy could strengthen its position against existing options, while provincial reimbursement decisions, testing requirements and treatment costs will determine uptake and equitable patient access.
Source: CA Newswire
